PerkinElmer announces agreement with Predictive Diagnostics that allows for comprehensive biomarker platform development aimed at accelerating drug development and diagnostics
PerkinElmer and Predictive Diagnostics (PDI), a clinical proteomics company and wholly owned subsidiary of Large Scale Biology, have entered into a collaborative partnership for advanced biomarker discovery technology to accelerate drug development and diagnostic testing.
PerkinElmer will provide access to PDI's proprietary biomarker amplification filter (Bamf) technology customised for PerkinElmer's Protof 2000 Maldi O-Tof mass spectrometer to create the 'industry standard' platform for biomarker discovery and analysis. PerkinElmer's Life and Analytical Sciences sales and marketing team will exclusively offer PDI's Bamf technology services to leading pharmaceutical companies and major research institutions.
PDI's Bamf technology is a comprehensive suite of in silico machine learning technologies and advanced informatics tools that use a simple blood test for the discovery of biomarker fingerprints to diagnose diseases utilising high-resolution mass spectrometry data.
PDI has developed its Bamf technology for use in serum-based tests for early diagnosis of cancer and other life-threatening diseases.
"Predictive Diagnostics is a recognised leader in biomarker analysis software.
"Its proprietary set of algorithms and informatics capabilities will complement our mass spectrometry and proprietary consumables offerings and complete our total solution for biomarker discovery and screening" said Peter Coggins, president of PerkinElmer Life and Analytical Sciences.
"We believe this solution will be enabling technology for our pharmaceutical, biotech, and academic customers in the proteomic biomarker field".
PerkinElmer's Protof 2000 is part of the company's high content proteomics solution, a comprehensive approach to proteomics research pioneered by PerkinElmer.
Using advanced, innovative technologies, like the Protof 2000 Maldi O-Tof, PerkinElmer has developed a suite of tools that achieve maximum meaningful data from any sample, improving results and reproducibility.
"PerkinElmer is the leader in state-of-the-art proteomic hardware and advanced purification solutions needed for advanced proteomic biomarker analysis," said Kevin Ryan, CEO of Predictive Diagnostics. "We are confident that the combined strength of PerkinElmer's proteomic hardware and PDI's portfolio of discovery and diagnostic solutions will add significant value to our pharmaceutical and life sciences customers."
